MedTrace Logo

A Repeat Dose Positron Emission Tomography Study With GSK1144814

NCT01209039 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-06-20

No results posted yet for this study

Summary

This study described in the present protocol consists of two parts. Part A is a multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ascending doses of GSK1144814. Part B is an open label design in healthy male subjects to assess the GSK1144814 Neurokinin1 receptor occupancy.

Conditions

Interventions

DRUG

GSK1144814

Multiple daily doses of GSK1144814 for 28 days

DRUG

GSK1144814

Multiple daily doses of GSK1144814 for 14 days

DRUG

GSK1144814

Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-01
Primary Completion
2009-10-25
Completion
2009-10-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01209039 on ClinicalTrials.gov